| 0.9452 0.045 (5.02%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.22 | 1-year : | 1.36 |
| Resists | First : | 1.04 | Second : | 1.16 |
| Pivot price | 0.93  |
|||
| Supports | First : | 0.84 | Second : | 0.7 |
| MAs | MA(5) : | 0.92 |
MA(20) : | 0.95 |
| MA(100) : | 1.09 |
MA(250) : | 1.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.7 |
D(3) : | 28.7 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 1.72 | Low : | 0.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMNN ] has closed below upper band by 39.9%. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.99 - 1 | 1 - 1 |
| Low: | 0.87 - 0.87 | 0.87 - 0.88 |
| Close: | 0.93 - 0.94 | 0.94 - 0.95 |
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
Mon, 20 Nov 2023
Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript - Yahoo Finance
Tue, 14 Nov 2023
IMUNON Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire
Tue, 14 Nov 2023
Transcript : Imunon, Inc., Q3 2023 Earnings Call, Nov 14, 2023 ... - Marketscreener.com
Tue, 14 Nov 2023
IMUNON's VP of R&D to Present at the Vaccines Summit-2023 - Yahoo Finance
Tue, 07 Nov 2023
IMUNON to Hold Third Quarter 2023 Financial Results and Business ... - Yahoo Finance
Thu, 19 Oct 2023
IMUNON treats first patient in ovarian cancer therapy trial - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 9.35e+006 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.12e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -17 % |
| Return on Assets (ttm) | 591.6 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 125000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -45.75 |
| EBITDA (p.s.) | 243902 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 1 |
| Dividend | 0 |
| Forward Dividend | 12030 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|